The role of indoleamine 2,3-dioxygenase in virus-induced asthma exacerbations

The role of indoleamine 2,3-dioxygenase in virus-induced asthma exacerbations - IDO and virus-induced asthma exacerbations

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33934

Enrollment

Registered

2008-05-26

Start date

2008-11-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma virus-induced asthma exacerbation

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for allergic asthma patients: - Controlled, intermittant to mild persistant asthma patients (according to the updated (2007) GINA guidelines); - FEV1 at baseline at least 80% of the predicted value; - baseline bronchial hyperresponsiveness to histamine (PC20histamine) between 0.25 and 8 mg/ml; - Skin-prick test positive to common allergens; - Patients are treated with inhaled beta-2-agonists on demand only (twice a week or less); - Age between 18 and 40 years;;Inclusion citeria for healthy subjects: - FEV1 at baseline at least 80% of the predicted value and baseline; - PC20histamine above 16 mg/ml; - Skin-prick test negative to common allergens; - Age between 18 and 40 years;

Exclusion criteria

Exclusion criteria: Exclusion criteria for allergic asthma patients: - Moderate to severe asthma patients (according to the updated (2007) GINA guidelines); - Allergic asthma patients with daily symptoms; - Nocturnal symptoms more than once a week; - Patients who have had an exacerbation during the past 6 months, as indicated by a course of systemic steroids or antibiotics; - Patients that used (inhaled) steroids less than 6 weeks prior to the study; - Smokers; - Ex-smokers ( 5 packyears); - Circulating antibodies against rhinovirus type 16; - Patients who are in close contact with young children ( 5 packyears); - Circulating antibodies against rhinovirus type 16; - Patients who are in close contact with young children (

Design outcomes

Primary

Measure	Time frame
With this project we will analyze the expression (mRNA and protein) and activity (tryptophan and kynurenine in serum and BALF) of indoleamine 2,3-dioxygenase. In addition we will determine cell counts and phenotype of inflammatory cells in BALF, viral load and inflammatory mediator production in epithelial cells and BALF and apoptosis markers in BALF cells and airway epithelial cells. Endogenous standards will be used to compare between healthy indiviuals and allergic asthma patients and between the two different time-points (pre- and post-RV16 exposure). Regression analysis will be performed to link these parameters to clinical details (FEV1, PC20histamine, symptom scores for asthma and common colds).	—

Measure

Time frame

With this project we will analyze the expression (mRNA and protein) and activity (tryptophan and kynurenine in serum and BALF) of indoleamine 2,3-dioxygenase. In addition we will determine cell counts and phenotype of inflammatory cells in BALF, viral load and inflammatory mediator production in epithelial cells and BALF and apoptosis markers in BALF cells and airway epithelial cells. Endogenous standards will be used to compare between healthy indiviuals and allergic asthma patients and between the two different time-points (pre- and post-RV16 exposure). Regression analysis will be performed to link these parameters to clinical details (FEV1, PC20histamine, symptom scores for asthma and common colds).

—

Secondary

Measure	Time frame
There are no secondary study parameters	—

Countries

Netherlands

Outcome results